Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.

摘要: Background & Aims Data regarding the health care costs of inflammatory bowel disease (IBD) in United States are limited. The objectives this study were to estimate direct Crohn's (CD) and ulcerative colitis (UC) States, describe distribution among inpatient, outpatient, pharmaceutical services, identify sociodemographic factors influencing these costs. Methods We extracted medical pharmacy claims from an administrative database containing insurance 87 plans 33 states, occurring between 2003 2004. identified cases CD UC using definition. For each case, we selected up 3 non-IBD controls. Claims classified as or according Current Procedural Terminology codes National Drug Codes. Costs based on paid amount claim. IBD-attributable estimated by subtracting for patients those with IBD. Logistic regression was used affecting Results 9056 10,364 UC. Mean annual $8265 $5066, respectively. CD, 31% attributable hospitalization, 33% outpatient care, 35% claims. corresponding 38%, 35%, 27%, significantly higher children younger than 20 years compared adults, but did not vary substantially sex region. Conclusions This demonstrates a substantial economic burden IBD can be inform policy.